Senior insider sale
SVP, General Counsel at ALLOGENE THERAPEUTICS, INC. — senior position signals high conviction
$63.0K
29.70K shares
What this filing means
DOUGLAS EARL MARTIN plans to sell 29.70K shares of ALLOGENE THERAPEUTICS, INC. valued at approximately $63.0K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 8/21/2026ACC: 0001737287-26-000023
Officer· SVP, General Counsel
Since Feb 2026
29.70K
Shares to sell
$63.0K
Approx. market value
81.72K
Acquired (3 months)
1
Planned
Securities Acquired — Last 3 Months1
Vesting of restricted stock unit award
Granted as part of issuer equity compensation plan
8/20/2026
81.72KTotal acquired81.72K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
8/20/2026 | Vesting of restricted stock unit award Granted as part of issuer equity compensation plan | 81.72K | — |
| Total | 81.72K | ||
Planned & Completed Dispositions1
NASDAQPlanned
Units to sell
29.70K
Market value
$63.0K
8/21/2026
Total
Units
29.70K
Value
$63.0K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
8/21/2026 | 29.70K | $63.0K | NASDAQ | Planned |
| Total | 29.70K | $63.0K | ||